JENTADUETO XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JENTADUETO XR (JENTADUETO XR).
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
| Metabolism | Linagliptin: minimal metabolism, primarily excreted unchanged in feces (80%) and urine (5%). Metformin: not metabolized, excreted unchanged in urine (90%) via tubular secretion. |
| Excretion | Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces. |
| Half-life | Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m². |
| Protein binding | Linagliptin: 70–80% bound to plasma proteins, saturable, concentration-dependent. Metformin: <5% bound to plasma proteins (negligible). |
| Volume of Distribution | Linagliptin: ~1110 L (large Vd, extensive tissue distribution). Metformin: 654–1372 L (mean ~654 L, indicating high tissue uptake). |
| Bioavailability | Linagliptin: ~30% oral bioavailability. Metformin: 40–60% oral bioavailability (extended-release); high interindividual variability. |
| Onset of Action | Oral: Linagliptin DPP-4 inhibition within 30 min post-dose; metformin reduces hepatic glucose production within 1–2 h. Peak effect after several days. |
| Duration of Action | Linagliptin: >24 h (once-daily dosing maintains >80% DPP-4 inhibition). Metformin: 12–24 h (extended-release formulation). Clinical glycemic effects persist over 24 h with regular dosing. |
| Molecular Weight | Metformin HCl: 165.63 Da; Empagliflozin: 450.9 Da; Fixed combination JENTADUETO XR: 165.63 and 450.9 Da for respective components. |
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | eGFR ≥45 mL/min/1.73 m²: no dose adjustment needed. eGFR 30-44: discontinue JENTADUETO XR; use individual components or lower dose metformin if appropriate. eGFR <30: contraindicated. |
| Liver impairment | Avoid use in patients with hepatic impairment (Child-Pugh Class A, B, or C) due to risk of lactic acidosis from metformin component. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years; no specific dosing guidelines available. |
| Geriatric use | In patients aged ≥65 years, assess renal function before initiating therapy. Use with caution due to age-related decline in renal function and increased risk of volume depletion. Consider starting at lower dose of empagliflozin (5 mg) and titrate gradually. |
| 1st trimester | Insulin is preferred; limited human data with metformin and empagliflozin; empagliflozin is not recommended due to potential renal effects in animal studies and lack of human data. |
| 2nd trimester | Insulin is preferred; metformin may be used if benefits outweigh risks; empagliflozin is not recommended. |
| 3rd trimester | Insulin is preferred; metformin may be used; empagliflozin is not recommended due to risk of neonatal hypoglycemia and potential renal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for JENTADUETO XR (JENTADUETO XR).
| Placental transfer | Metformin crosses the placenta; empagliflozin is likely to cross based on molecular weight and animal studies. |
| Breastfeeding | Metformin is excreted into breast milk in low amounts; empagliflozin excretion is unknown but likely minimal due to high protein binding. Use with caution, especially in preterm infants or those with renal impairment. |
■ FDA Black Box Warning
Lactic Acidosis: Metformin-associated lactic acidosis (MALA) is a rare but serious adverse event; risk factors include renal impairment, hypoxia, sepsis, and acute congestive heart failure.
| Serious Effects |
Severe renal impairment (eGFR <30 mL/min/1.73 m²)Acute or chronic metabolic acidosis (including diabetic ketoacidosis)Hypersensitivity to metformin or empagliflozinIntravascular iodinated contrast media (use) in patients with hepatic or renal impairment
| Precautions | Lactic acidosis risk (metformin component), Pancreatitis (linagliptin), Acute kidney injury or renal impairment (metformin), Hypoglycemia risk when used with insulin or sulfonylureas, Hypersensitivity reactions (angioedema, anaphylaxis, urticaria) |
| Food/Dietary | JENTADUETO XR should be taken with food to minimize metformin-related gastrointestinal side effects. Avoid excessive alcohol consumption (≥3 drinks/day or binge drinking) due to increased risk of lactic acidosis. Metformin may interfere with vitamin B12 absorption; ensure adequate dietary intake of B12 or consider supplementation. No specific food restrictions for linagliptin. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies show no fetal harm. Limited human data; risk cannot be excluded. First trimester: no confirmed risk. Second/third trimester: theoretical risk of neonatal lactic acidosis with metformin; avoid. |
| Fetal Monitoring | Monitor blood glucose, HbA1c, renal function (serum creatinine) before and during therapy. Assess fetal growth and amniotic fluid volume if used in pregnancy. |
| Fertility Effects | No known adverse effects on fertility. Metformin may improve ovulation in women with PCOS. |
| Clinical Pearls | JENTADUETO XR combines linagliptin (DPP-4 inhibitor) and metformin (biguanide). Metformin component requires renal monitoring; eGFR must be ≥30 mL/min/1.73 m². Linagliptin is primarily hepatobiliary excreted, reducing drug accumulation risk in renal impairment. Avoid in metabolic acidosis, including diabetic ketoacidosis. Monitor for lactic acidosis, especially in hypoperfusion or sepsis. Administer with meals to reduce metformin GI intolerance. No dose adjustment needed for linagliptin in renal impairment. Use caution in patients with CHF (NYHA III-IV) due to metformin-associated lactic acidosis risk. Do not use in type 1 diabetes. |
| Patient Advice | Take this medication exactly as prescribed, once daily with a meal to reduce stomach upset. · Do not crush, cut, or chew the extended-release tablet; swallow whole. · Monitor for symptoms of lactic acidosis: unusual muscle pain, tiredness, difficulty breathing, stomach pain, or dizziness. · Check blood sugar regularly as directed by your healthcare provider. · Report any signs of pancreatitis: severe stomach pain that may radiate to your back, with or without vomiting. · Avoid excessive alcohol intake as it increases risk of lactic acidosis and low blood sugar. · Inform your doctor about any kidney problems; this drug may not be suitable. · Stop taking this drug and seek medical attention if you experience an allergic reaction (rash, hives, swelling of face/lips/tongue). · Do not use this drug for type 1 diabetes or diabetic ketoacidosis. · Store at room temperature, away from moisture and heat. |